What FDA‑approved adjunct medications are available to augment antidepressant treatment in adults whose depressive symptoms have not improved after an adequate trial?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

FDA-Approved Adjunct Medications to Antidepressants

For adults with major depressive disorder who have not responded adequately to antidepressant monotherapy, the FDA-approved adjunctive medications are the atypical antipsychotics: aripiprazole, brexpiprazole, cariprazine, quetiapine extended-release, and the olanzapine-fluoxetine combination, along with intranasal esketamine for treatment-resistant depression. 1, 2

First-Line Adjunctive Options: Atypical Antipsychotics

The atypical antipsychotics represent the most extensively studied and FDA-approved augmentation strategy for inadequate antidepressant response:

Aripiprazole

  • First FDA-approved adjunctive agent (November 2007) for major depressive disorder 3
  • Dosing: 2-3 mg/day (lower than doses used for schizophrenia or bipolar disorder) 4
  • Demonstrated clinically meaningful efficacy in three large-scale, 6-week randomized controlled trials 3
  • Mechanism: Partial agonist at dopamine D2/D3 and serotonin 5-HT1A receptors; antagonist at 5-HT2A receptors 3
  • Key caveat: Higher incidence of akathisia compared to schizophrenia trials, though most cases are mild-to-moderate and rarely lead to discontinuation (5/1090 patients across trials) 3

Brexpiprazole

  • Approved dosing: 2-3 mg once daily 5
  • Advantage over aripiprazole: Lower intrinsic D2 activity suggests reduced potential for activation-like adverse effects such as akathisia 5
  • Effective in both minimal responders (>0% to <25% improvement) and partial responders (≥25% to <50% improvement) to antidepressants 6
  • In minimal responders: Mean difference of -2.47 points on MADRS (Cohen's d = 0.41, P<0.001) 6
  • Well tolerated in trials up to 52 weeks 5

Other FDA-Approved Atypical Antipsychotics

  • Cariprazine: FDA-approved for adjunctive treatment 1
  • Quetiapine extended-release: Approved in 2009 2
  • Olanzapine-fluoxetine combination: Approved in 2009 2

Critical Considerations for Atypical Antipsychotics

Weigh benefits against metabolic and neurological risks: weight gain, akathisia, and tardive dyskinesia are significant concerns 1. These medications should be reserved for patients with documented inadequate response to antidepressant monotherapy, not used as first-line treatment.

Second-Line Option: Esketamine (Treatment-Resistant Depression)

Intranasal esketamine is FDA-approved specifically for treatment-resistant depression (defined as failure of at least 2 adequate antidepressant trials) 7:

  • Administered twice weekly as augmentation to ongoing oral antidepressant 7
  • Improves depressive symptoms and remission rates at up to 28 days of follow-up 7
  • Evidence supports longer-term maintenance use 7

Important Restrictions

  • Risk Evaluation and Mitigation Strategy (REMS) requirements: Mandatory pharmacy and health care setting certification, plus 2-hour post-treatment monitoring 7
  • Not recommended as initial treatment—reserved for patients who have failed or not tolerated previous therapies 7
  • Also approved for depressive symptoms with acute suicidal ideation/behavior, though effectiveness in preventing suicide has not been established 7

Ketamine Infusion

While not FDA-approved for depression, ketamine infusion shows efficacy in treatment-resistant depression 7:

  • Significant improvement in depressive symptoms at 24 hours, persisting up to 7 days when added to ongoing antidepressant 7
  • Lacks long-term efficacy and safety data 7
  • The VA/DoD guideline supports ketamine infusions as adjunctive treatment for short-term reduction in suicidal ideation 7

Clinical Decision Algorithm

  1. After inadequate response to first antidepressant trial: Consider atypical antipsychotic augmentation (aripiprazole, brexpiprazole, or others listed above)

    • Start with aripiprazole 2-3 mg/day or brexpiprazole 2-3 mg/day
    • Choose brexpiprazole if akathisia is a concern
    • Monitor for weight gain, metabolic effects, and extrapyramidal symptoms
  2. After failure of 2+ adequate antidepressant trials (treatment-resistant depression): Consider esketamine augmentation

    • Requires REMS-certified facility
    • Twice-weekly intranasal administration with 2-hour monitoring
    • Continue concurrent oral antidepressant
  3. For severe treatment-resistant depression with suicidal ideation: Consider ketamine infusion or esketamine in specialized settings 7

Evidence Quality Context

The 2023 American College of Physicians guideline notes that certainty of evidence is low for most second-step treatment comparisons, with different switching and augmentation strategies providing similar symptomatic relief 8. However, the atypical antipsychotics have the most robust FDA approval data and represent the standard of care for augmentation. The 2022 VA/DoD guideline provides strong support for esketamine/ketamine specifically in treatment-resistant populations 7.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.